Abstract
Adrenocortical carcinoma (ACC) is a rare tumour with a poor prognosis. Cisplatin is the most widely tested cytotoxic agent in this disease. A total of 18 patients with advanced ACC were enrolled. Cytotoxic therapy consisted of etoposide (VP16) (100 mg m(-2) day(-1) on days 1-3) and cisplatin (100 mg m(-2) day(-1) on day 1) every 4 weeks. Mitotane treatment was maintained during chemotherapy in 14 patients. A complete response was observed in three cases and a partial response in three cases, giving an overall response rate of 33%. Tumour response was observed in three of the six patients with progressive disease during treatment with mitotane given at an effective dosage, as shown by serum levels >14 mg l(-1). Toxic effects were as expected and were non-life-threatening; no treatment interruption was required.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Consortia
Rights and permissions
About this article
Cite this article
Bonacci, R., Gigliotti, A., Baudin, E. et al. Cytotoxic therapy with etoposide and cisplatin in advanced adrenocortical carcinoma. Br J Cancer 78, 546–549 (1998). https://doi.org/10.1038/bjc.1998.530
Issue Date:
DOI: https://doi.org/10.1038/bjc.1998.530
This article is cited by
-
Management of adrenocortical carcinoma: a consensus statement of the Italian Society of Endocrinology (SIE)
Journal of Endocrinological Investigation (2016)
-
Management of adrenal cancer: a 2013 update
Journal of Endocrinological Investigation (2014)
-
Pharmacotherapy of Pathological States of Adrenal Glands (Review)
Pharmaceutical Chemistry Journal (2013)
-
Mixed corticomedullary adrenal carcinoma
Surgery Today (2013)
-
Four clinically utilized drugs were identified and validated for treatment of adrenocortical cancer using quantitative high-throughput screening
Journal of Translational Medicine (2012)